Natco Pharma share news, announcements and annual reports
NSE: NATCOPHARMBSE: 524816Pharmaceuticals & BiotechnologySmall Cap
Natco Pharma Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Dec 1995 on NSE
Last close ₹782.40down ₹5.15 (0.65%)BSE ₹782.50
Share price at the NSE close on 30 Oct 2026. Previous close ₹787.55.
30 Oct: open ₹792.05, high ₹800.90, low ₹779.50
52-week range of traded prices to 30 Oct 2026
₹773.60Low, 22 Oct 2026₹1,226.80High, 12 May 2026
- Next results date: the board meets on 13 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,348 Cr380th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.41
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.58%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 8.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.08
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 3,21,54744.0% delivered
Natco Pharma board meetings
128 filed, newest first. Page 2 of 3.
Oct 2018
Jul 2018
May 2018
23 May · Board meeting
16 May · Board meeting
Jan 2018
Dec 2017
11 Dec · Board meeting
Nov 2017
2 Nov · Board meeting
Oct 2017
Aug 2017
7 Aug · Board meeting
Jul 2017
May 2017
Feb 2017
Nov 2016
11 Nov · Board meeting
Aug 2016
9 Aug · Board meeting
Jul 2016
May 2016
Mar 2016
Feb 2016
Jan 2016
Nov 2015
Sep 2015
Aug 2015
May 2015
22 May · Board meeting
Feb 2015
Jan 2015
30 Jan · Board meeting
To consider among other things, the unaudited financial Results for the quarter ended December 31, 2014, to consider Interim Dividend, if any, for the financial year 2014-15 and related matters etc.
Nov 2014
13 Nov · Board meeting
Board of Directors at their meeting held on November 12, 2014, taken on record the following: 1. Mr. P.S.R.K. Prasad, Executive Vice President (Corporate Engineering Services) appointed as Additional Director of the Company who will be in the wholetime employment of the Company. 2. Mr. S.V.V.N. Appa Rao, Vice President (Finance & Accounts) appointed as Interim (Chief Financial Officer) of the Company.
Oct 2014
31 Oct · Board meeting
To consider among other things, the un-audited financial Results for the quarter ended September 30, 2014 and related matters.
Aug 2014
13 Aug · Board meeting
Jul 2014
May 2014
Feb 2014
13 Feb · Board meeting
Board of Directors of the Company at its meeting held on February 13, 2014 has considered and approved the following: (1) Mr. Vivek Chhacchi, Nominee Director of CX Securities Ltd. and Mr. D. G. Prasad, Independent Director inducted as Additional Directors. Mr. Nitin Jagannath Deshmukh resigned as a Director due to his personal preoccupation.3 Feb · Board meeting
To consider among other things, the unaudited financial Results for the quarter ended December 31, 2013, to consider Interim Dividend, if any, for the financial year 2013-14 and related matters etc.
Nov 2013
5 Nov · Board meeting
To consider among other things, the unaudited financial results for the quarter ending September 30, 2013 and related matters.
Oct 2013
Aug 2013
14 Aug · Board meeting
2 Aug · Board meeting
To consider among other things, the unaudited financial Results for the quarter ended June 30, 2013, convening of Annual General Meeting and related matters etc.
Jun 2013
4 Jun · Board meeting
To consider the audited consolidated financial statements.
May 2013
20 May · Board meeting
To consider among other things, approval of the Audited Results for the quarter ending March, 2013 along with Audited Annual Accounts for the year 2012-2013 and related matters.
Jan 2013
31 Jan · Board meeting
To consider among other things, the unaudited financial Results for the quarter ended December 31, 2012, to consider Interim Dividend, if any, for the financial year 2012-13 and related matters etc.
Nov 2012
9 Nov · Board meeting
Board of Directors of the Company at its meeting held on November 08, 2012, has allotted 2,25,122 equity shares of Rs. 10/- each to the eligible employees under ESOP. Further the Company has informed that the Company has acquired, during the quarter, 51% of the paid-up equity capital of NATCO Organics Ltd.
Oct 2012
29 Oct · Board meeting
To consider among other things, the unaudited financial Results for the quarter ended September 30, 2012 and related matters etc.
Aug 2012
11 Aug · Board meeting
Board of Directors of the Company at its meeting held on August 11, 2012 had authorised Mr. V. C. Nannpaneni, Chairman and Managing Director to fix up the date, time and Venue of the Annual General Meeting as also Book Closure Dates.
Jul 2012
31 Jul · Board meeting
To consider among other things, the unaudited financial Results for the quarter ended June 30, 2012, convening of Annual General Meeting and related matters etc.
May 2012
29 May · Board meeting
Board of Directors of the Company at its meeting held on May 28, 2012, inter alia, has transacted the following : Based on the recommendations of the Remuneration Committee of the Board of Directors, the Board, subject to the approval of members at the ensuing General Meeting, had revised the remuneration payable to Shri V. C. Nannapaneni, Chairman and Managing Director of the Company and redesignated Mr. Rajeev Nannapaneni as Vice Chairman & CEO besides increasing his remuneration w.e.f. June 01, 2012 for a period of three years.16 May · Board meeting
To consider among other things, approval of the Audited Results for the quarter ending March, 2012 along with Audited Annual Accounts for the year 2011-2012 and related matters.
Feb 2012
13 Feb · Board meeting
Board of Directors at their meeting held on February 09, 2012 have inducted Mr. Nitin Deshmukh as an Additional Director of the Company, who has been nominated by Kotak India Venture Fund I.